Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Heat shock protein 90 (Hsp90) is a chemical in the body that is involve in the promotion of
cancer. SNX-5422 is an experimental drug that blocks Hsp90.